866-945-0263 | enquiries@arrowheadpublishers.com

pain management

  • July 17, 2013

    Reducing Experimental Error in Analgesic Clinical Trials

    Pharmaceutical companies spend large amounts of time perfecting their protocol and selecting quality sites so that the efficacy of their drug can be statistically demonstrated in clinical trials. However, an equal amount of effort is rarely placed on other aspects of clinical trials that may lead to optimizing their success such as patient education and analgesic model manipulations. 

  •  August 1, 2013

    Advances in Chronic Migraine Treatment

    The 7th Annual Pain Therapeutics Summit East is the East Coast complement to the 7th Annual Pain Therapeutics Summit held on the West Coast. Year over year growth of this event necessitated an expansion into a bi-coastal pain summit. 

  • September 8, 2016

    Cara Therapeutics to Present Novel Kappa Opioid Receptor Agonist Research at Upcoming Pain Summit

    Cara Therapeutics has recently resumed clinical trials for its novel kappa opioid receptor agonist CR845 in managing acute and chronic pain. 

  • August 2, 2016

    Centrexion Therapeutics to Present on Collaborative Pain Research with BioXcel at 10th Annual Pain & Migraine Therapeutics Summit
    Centrexion Therapeutics has announced a collaborative agreement with BioXcel to develop and commercialize innovative chronic pain therapeutics.
  • July 10, 2013

    Chronic Pain Therapy Research From Dogs To Humans

    The study of chronic pain has led researchers down a variety of paths with the goal of finding a means to alleviate suffering in the most effective way possible. In one study, University of Colorado researchers are currently examining an effective treatment for chronic pain in dogs as a means to further treatment possibilities for humans. 

  • September 27, 2013

    Microelectrode Arrays for Pain Research and Drug Development

    Large amounts of information on the cellular and molecular mechanisms involved in sensory processing in the peripheral nervous system have been gained in vitro using neurons isolated from dorsal root ganglia (DRG). Electrophysiological recordings from cultured DRG neurons were mainly obtained by the use of patch-clamp, an approach offering a level of throughput often incompatible with the objectives of the pharmaceutical industry.

  • June 30, 2016

    Precision Treatments for Pain Discovered by Research Team at Yale University to be Shared at 10th Annual Pain Therapeutics Summit
    An estimated 100 million people in America are in need of better, more personalized treatments for pain, and a team at Yale University has proven how it should be done. Their research has shown that by using a pharmacogenomics approach which analyzes the genomes of patients, it is possible to predict and therefore reduce the likelihood of adverse drug effects. 
  • August 1, 2016

    Research on an fMRI-Based Neurologic Signature of Physical Pain to be Presented at Upcoming 10th Annual Pain & Migraine Therapeutics Summit

    As persistent pain is solely measured by self-report, research is currently being conducted to find objective methods of identifying physical pain in the brain. Researcher teams from various universities have discovered an imaging-based signature to predict pain sensitivity using functional magnetic resonance imaging (fMRI) and machine learning. 

  • August 4, 2016

    Vivozon to Present Practical Methodology in Identifying Antionociceptive Multi-Target Drugs at Upcoming 10th Annual Pain Therapeutics Summit
    As the steady decline of newly developed single-targeted drugs is becoming a challenge in the field, researchers are preferring to use a practical methodology in identifying antionociceptive multi-target drugs. The design of this approach allows for drugs to reflect multifactorial diseases caused by intricate networks of various mechanisms. A recent review on the revolutionary trend in pursuing multi-targeting drugs has been released by several researchers in the field of neuropathic pain. 

Contact Us

PO Box 96
Chanhassen, MN 55317 USA

Speaker Opportunities

If you are interested in speaking at one of Arrowhead's conferences or would like to suggest a conference theme for which you have particular expertise, we'd like to hear from you.

Sponsor/Exhibitor Opportunities

Arrowhead sponsorship and exhibitor levels are designed to give your organization the highest level of exposure and opportunity to market products and branding in an environment that is targeted toward facilitating professional networking. We can also build tailor-made packages that will meet your organization's marketing budget and goals. Arrowhead sponsorships are proven to help grow businesses through direct and targeted exposure to industry leaders and decision makers. To gain critical industry exposure via our sponsorship and exhibiting opportunities, please contact us.